Protocol Ledger

NCT07073820 · Phase II · TERMINATED

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Interventional Phase II clinical trial protocol NCT07073820 sponsored by Pfizer in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-10 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07073820
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07073820
Protocol FieldVerified Registry Value
NCT IdentifierNCT07073820
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2025-11-10
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07073820
Hospital Research SiteLocationSite Profile
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->
Royal Prince Alfred HospitalCamperdown, AustraliaOpen Hospital Dossier ->
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI